delgocitinib brand name corectim pharmaceutical drug treatment autoimmune disorders hypersensitivity including inflammatory skin delgocitinib developed japan tobacco approved japan treatment atopic united states delgocitinib phase iii clinical trials food drug administration granted delgocitinib fast track designation topical treatment adults moderate severe chronic hand delgocitinib works blocking activation jakstat signaling pathway contributes pathogenesis chronic inflammatory skin antineoplastic immunomodulatory drug article stub help wikipedia expanding ithttpsenwikipediaorgwikidelgocitinib